The short answer
Confirm the valerian species before combining this root product with trihexyphenidyl. If it is Valeriana officinalis, added drowsiness is a reasonable concern; the generic name alone does not establish that identity.
What this answer covers
Generic root/rhizome name does not establish Valeriana officinalis.
- Supplement or preparation
- Radix et Rhizoma Valerianae
- Medication ingredient
- trihexyphenidyl
The medicine can affect alertness
Atropine-like effects, drowsiness, confusion, constipation and urinary retention; glaucoma and obstruction precautions. These medication warnings do not supply a supplement-specific adverse-event rate.
What the supplement evidence shows
Federal valerian guidance concerns Valeriana officinalis and advises caution with sedatives. The generic root name does not confirm that species or a particular extract, so this warning requires product confirmation.
Keep the preparation and outcome clear
Dose, formulation and other ingredients matter. No exact-pair trial identified here established how much impairment would increase, and a negative result for one product alone does not prove the combination safe.
Review co-use and daily activities
Discuss the product with the prescriber or pharmacist before adding it. Avoid driving while drowsy or dizzy. No exact protective spacing interval was established, and a supplement should not be used to counteract medication impairment.
Evidence and practical considerations
Side effects & toxicity
Unconfirmed generic valerian identity prevents validation of the original claim with V.officinalis evidence; separate confirmed-species precaution retained.
- Exact scope
- Generic root/rhizome name does not establish Valeriana officinalis. with Oral trihexyphenidyl hydrochloride tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed trihexyphenidyl
Atropine-like effects, drowsiness, confusion, constipation and urinary retention; glaucoma and obstruction precautions.
How this applies: Exact trihexyphenidyl RxCUI 10811 IN, with stated salt/formulation/route bridge.
No exact supplement-combination incidence or validated protective spacing; salt, route and release form limits apply.
Source 2: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
Sedation is possible but not proven; guidance advises avoiding use with sedatives. The material discussed is Valeriana officinalis.
How this applies: Interpreted for trihexyphenidyl only within the stated exact preparation and endpoint limits.
No exact trihexyphenidyl combination trial; original population, preparation and endpoint restrictions apply. No quantified pair risk or protective dose interval.
Research assessment: · Open full citations ↗
Side effects & toxicity
If confirmed as Valeriana officinalis, added drowsiness with trihexyphenidyl is a conditional concern.
- Exact scope
- Confirmed Valeriana officinalis root product. with Oral trihexyphenidyl hydrochloride tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No exact-pair incidence or universally protective timing interval.
Factors that may matter: Preparation; Dose; Other medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed trihexyphenidyl
Atropine-like effects, drowsiness, confusion, constipation and urinary retention; glaucoma and obstruction precautions.
How this applies: Exact trihexyphenidyl RxCUI 10811 IN, with stated salt/formulation/route bridge.
No exact supplement-combination incidence or validated protective spacing; salt, route and release form limits apply.
Source 2: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
Sedation is possible but not proven; guidance advises avoiding use with sedatives. The material discussed is Valeriana officinalis.
How this applies: Interpreted for trihexyphenidyl only within the stated exact preparation and endpoint limits.
No exact trihexyphenidyl combination trial; original population, preparation and endpoint restrictions apply. No quantified pair risk or protective dose interval.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact trihexyphenidyl article with formulation-specific evidence and uncertainty. |
Article revision: 6264c45d5b851bb1
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.